NCT04611802: An ongoing trial by Novavax
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 4 months from now.
Full data
Full entry on ClinicalTrials.gov | NCT04611802 |
---|---|
Title | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Dec. 27, 2020 |
Completion date | April 10, 2023 |
Required reporting date | April 10, 2026, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |